C-Forward: Efficacy and Safety of BEM/RZR vs SOF/VEL in Subjects With Chronic HCV

The study is looking for adults aged between 18 and 85 years old. You should have chronic hepatitis C, which means you've had the infection for a long time. It's important that you haven't taken any direct-acting antiviral (DAA) medicines for hepatitis C before, as this study is for people new to these types of treatments.

Your liver health is also a key factor. You can either have no liver scarring (cirrhosis) or only mild scarring that isn't causing serious problems. If you also have HIV, your HIV should be well-controlled with your current medications, and you must meet specific blood test requirements.

There are some reasons why you wouldn't be able to join. For example, if you are pregnant or breastfeeding, or if you also have hepatitis B. The study also cannot include individuals with serious liver complications, such as severe liver scarring or liver cancer. If you are struggling with alcohol or drug use that might make it hard to stick to the study's plan, this might also exclude you.

Details about taking part in this specific study are not fully described here. However, typically in a clinical trial like this, you would have an initial screening visit to check if you're suitable. If you qualify, you'd begin the study treatment, which involves taking medication regularly, as instructed. You would have several follow-up visits to the clinic. These visits usually involve blood tests, physical examinations, and questions about how you're feeling and any side effects you might be experiencing. These visits help the doctors monitor your health and the effectiveness of the treatment. The total duration of your participation, including treatment and follow-up, would be clearly explained to you before you agree to join.